Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus - Trial NCT06421701
Access comprehensive clinical trial information for NCT06421701 through Pure Global AI's free database. This Phase 1 trial is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Second Affiliated Hospital, School of Medicine, Zhejiang University
Timeline & Enrollment
Phase 1
Jun 01, 2024
May 31, 2026
Primary Outcome
The proportion of subjects with DLT,The proportion of subjects with adverse events
Summary
This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this
 study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with
 refractory/relapsed systemic lupus erythematosus.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421701
Non-Device Trial